Status:
RECRUITING
TLN-372 in Advanced KRAS Mutant Solid Tumors
Lead Sponsor:
Treeline Biosciences, Inc.
Conditions:
KRAS Mutant Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with ad...
Eligibility Criteria
Inclusion
- Patients must have measurable disease at study entry.
- Patients must have locally advanced or metastatic KRAS mutant solid tumors.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function.
Exclusion
- Patients must not have active brain metastases.
- Patients must not have current or past history of central nervous system (CNS) involvement.
- Patients must not have major surgery or severe trauma within 4 weeks prior to the start of the study.
- Patients must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places patients at unacceptable risk of participating in this study.
- Patients must not have clinically significant cardiovascular disease.
- Pregnant or lactating.
- Conditions that could affect drug absorption.
Key Trial Info
Start Date :
September 29 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2032
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT07204340
Start Date
September 29 2025
End Date
April 1 2032
Last Update
December 10 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215-5450
2
START Midwest
Grand Rapids, Michigan, United States, 49546
3
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021-3402
4
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203